Sarepta Therapeutics - 53 Year Dividend History | SRPT

Historical dividend payout and yield for Sarepta Therapeutics (SRPT) since 1971. The current TTM dividend payout for Sarepta Therapeutics (SRPT) as of April 19, 2024 is $0.00. The current dividend yield for Sarepta Therapeutics as of April 19, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.944B $1.243B
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
Stock Name Country Market Cap PE Ratio